Results
|
172421.
|
|
|
172422.
|
|
|
172423.
|
|
|
172424.
|
|
|
172425.
|
|
|
172426.
|
|
|
172427.
|
|
|
172428.
|
|
|
172429.
|
|
|
172430.
|
|
|
172431.
|
|
|
172432.
|
|
|
172433.
|
|
|
172434.
|
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. [electronic resource] by
- Rex, J H
- Pfaller, M A
- Galgiani, J N
- Bartlett, M S
- Espinel-Ingroff, A
- Ghannoum, M A
- Lancaster, M
- Odds, F C
- Rinaldi, M G
- Walsh, T J
- Barry, A L
Producer: 19970619
In:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 24
Availability: No items available.
|
|
172435.
|
|
|
172436.
|
|
|
172437.
|
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat. [electronic resource] by
- Whiteside, Garth T
- Harrison, James E
- Pearson, Michelle S
- Chen, Zhengming
- Fundytus, Marian E
- Rotshteyn, Yakov
- Turchin, Paul I
- Pomonis, James D
- Mark, Lilly
- Walker, Katharine
- Broglé, Kevin C
Producer: 20050328
In:
The Journal of pharmacology and experimental therapeutics vol. 310
Availability: No items available.
|
|
172438.
|
|
|
172439.
|
|
|
172440.
|
|